Joint Formulary & PAD

Certolizumab pegol - Rheumatoid arthritis

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Red
Formulations :
  • Subcutaneous injection (sc)
Associated Icons :
Restrictions / Comments :

PAD Profile

ChemicalSubstance :
Certolizumab pegol
Indication :
Rheumatoid arthritis
Group Name :
Keywords :
RA, Biologic, NICE, immunosuppressant, Cytokine modulator, TNF Alpha Inhibitor, DMARD, bDmard, Disease modulating, Rheumatology
Brand Names Include :
Cimzia
Important Information :
Severe disease only
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
3

Other Indications

Below are listed other indications that Certolizumab pegol is used to treat.

Committee Recommendations (2)

The Surrey Heartlands Integrated Care System Area Prescribing Committee agreed the reviewed and updated rheumatoid arthritis pathways (moderate and severe).

The Surrey Heartlands ICS Area Prescribing Committee have agreed an update of the Rheumatoid Arthritis High Cost DMARDs Drug Treatment Pathway. 

The pathway has been updated following guidance from the Regional Medicines Optimisation Committee in May 2020, in relation to the sequential use of biologic medicines.